Pulmonary Arterial Hypertension clinical trials at UCLA
16 in progress, 8 open to eligible people
Ralinepag to Improve Treatment Outcomes in PAH Patients
open to eligible people ages 18 years and up
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)…
Los Angeles, California and other locations
Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)
open to eligible people ages 1-17
The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to <18 years of age with PAH World Health Organization (WHO) Group 1 on standard of…
Los Angeles, California and other locations
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
open to eligible people ages 18 years and up
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Los Angeles, California and other locations
Novel Index (PIMR) in PAH
open to eligible people ages 18 years and up
The chief regulator of resistance in pulmonary arterial hypertension (PAH) is the small arteries. In the heart, the invasive measurement of the resistance of the small arteries has been shownto be safe, easy, reliable, and prognostic. This study is…
Los Angeles, California
Sotatercept for PAH Treatment (MK-7962-004/A011-12)
open to eligible people ages 18 years and up
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study…
Los Angeles, California and other locations
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
open to eligible people ages 18-80
This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.
Torrance, California and other locations
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
open to eligible people ages 18-80
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension…
Los Angeles, California and other locations
Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
open to eligible people ages 0-20
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The…
Los Angeles, California and other locations
Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)
Sorry, in progress, not accepting new patients
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) on time to clinical…
Los Angeles, California and other locations
Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Sorry, accepting new patients by invitation only
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
Los Angeles, California and other locations
Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Los Angeles, California and other locations
Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
Sorry, in progress, not accepting new patients
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial…
Los Angeles, California and other locations
Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH
Sorry, accepting new patients by invitation only
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are severe clinical conditions that, despite advances in therapeutics over the past 20 years, lead to serious morbidity and mortality. Guidelines on the…
Los Angeles, California
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Sorry, in progress, not accepting new patients
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary…
Torrance, California and other locations
Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study
Sorry, in progress, not accepting new patients
The objectives of this study are to evaluate the safety of RT234 and the effects of RT234 on exercise capacity as assessed by Cardiopulmonary Exercise Testing (CPET) and six minute walk testing (6MWT) as well as exertional symptoms in patients with…
Los Angeles, California and other locations
Utility of Submaximal CPET in Treatment Management of PAH
Sorry, not yet accepting patients
Pulmonary hypertension (PH) is associated with worsening breathlessness and exercise capacity, right-heart failure, and adverse outcomes including increased mortality. Moreover, PH disease progression can be rapid; pharmaceutical intervention in…
Torrance, California and other locations
Our lead scientists for Pulmonary Arterial Hypertension research studies include Juan C. Alejos, MD Rajan Saggar, MD Jaime Deville Ronald Oudiz, MD Adam J. Brownstein, MD Rushi Parikh, MD Suzanne Kafaja, MD Richard N. Channick, MD.
Last updated: